<DOC>
	<DOCNO>NCT02133170</DOCNO>
	<brief_summary>This parallel 3-group , multicenter , prospective , randomize , single-blind ( evaluator ) control pilot trial , 38- week follow-up . Patients diagnose bipolar disorder ( BD ) accord DSM -5 criterion mild depression subsyndromal depressive symptom assign one follow 3 treatment group : 1 ) psychopharmacological treatment plus Mindfulness Based Cognitive Therapy ( MBCT ) ; 2 ) psychopharmacological treatment plus structured group psychoeducation ; 3 ) treatment usual ( TAU ) , include standard psychiatric care standard pharmacologic treatment .</brief_summary>
	<brief_title>`` Mindfulness v Psychoeducation Bipolar Disorder ''</brief_title>
	<detailed_description>This parallel 3-group , multicenter , prospective , randomize , single-blind ( evaluator ) control pilot trial , 38- week follow-up . Patients diagnose bipolar disorder ( BD ) accord DSM -5 criterion mild depression subsyndromal depressive symptom assign one follow 3 treatment group : 1 ) psychopharmacological treatment plus Mindfulness Based Cognitive Therapy ( MBCT ) ; 2 ) psychopharmacological treatment plus structured group psychoeducation ; 3 ) treatment usual ( TAU ) , include standard psychiatric care standard pharmacologic treatment . After write informed consent sign , patient meet inclusion criterion randomize ( 2:2:1 ratio ) Random Allocation Software . All three group assess baseline ( t0 ) , immediately complete program ( t1 ; 8 week ) follow-up six month randomization . The assessment include follow variable : depression , anxiety , general social cognition , global functioning , BDNF , clinical variable . The evaluator collect biomarkers clinical psychometric data blind treatment . The interrater variability researcher check .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<criteria>Age : 1860 year BD type I II , clinical remission acute mood episode least three month prior study Having present acute affective episode past 3 year Having present least two depressive episode throughout life . Monotherapy combination mood stabilizer ( lithium , valproate , carbamazepine lamotrigine ) optimal dos ( ie , serum level within therapeutic range : 0.61.2 mEq / L lithium , 50100 ug / ml valproate , 512 mcg / mL carbamazepine ) , quetiapine monotherapy combination aforementioned stabilizer , oral atypical antipsychotic combination antidepressant Hamilton Depression Rating Scale [ HDRS ] 17 score ≥ 8 ≤ 19 Young Mania Rating Scale [ YMRS ] score &lt; 8 Being able understand comply requirement trial Written consent participate study . Any acute mood episode 12 week start trial . Any current DSM 5 diagnosis different bipolar disorder ( include substance alcohol use disorder time study entry , except complete remission . Not applicable nicotine caffeine ) Risk suicide self/hetero aggressiveness Pregnancy Severe unstable medical pathology . Patients currently receive structure psychotherapy structure group psychoeducation bipolar disorder , receive structured psychoeducation past 5 year Patients treat different mood stabilizer lithium , valproate , carbamazepine , lamotrigine , classic antipsychotic antidepressant monotherapy time randomization Treatment depot antipsychotic Participation another clinical trial within 4 week prior randomization Mental Retardation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>BIPOLAR DISORDER</keyword>
	<keyword>DEPRESSIVE SYMPTOMS</keyword>
	<keyword>MINDFULNESS</keyword>
	<keyword>PSYCHOEDUCATION</keyword>
	<keyword>BIPOLAR PATIENTS WITH DEPRESSIVE SYMPTOMS</keyword>
</DOC>